Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

V. Farooq, Asim; Degli Esposti, Simona; Popat, Rakesh; Thulasi, Praneetha; Lonial, Sagar; K. Nooka, Ajay; Jakubowiak, Andrzej; W. Sborov, Douglas; Zaugg, Brian; Badros, Ashraf; H. Jeng, Bennie; S. Callander, Natalie; Opalinska, Joanna; Baron, January; Piontek, Trisha; Byrne, Julie; Gupta, Ira; Colby, Kathryn

doi:10.1007/s40123-020-00280-8

Public

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Published in Ophthalmology and Therapy • Jul 25, 2020

Authors:

Asim V. Farooq

Simona Degli Esposti

Rakesh Popat

Abstract

INTRODUCTION: Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody-drug conjugate (ADC; or immunoconjugate) that delivers a cytotoxic payload, monomethyl auristatin F (MMAF), to myeloma ...

Subject

Medicine

Blurred vision

Multiple myeloma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!